Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517412 | 1.00 | DRD2 (0.44) | DRD2DRD3HTR1DSCN9ASCN5A | |
| SCHEMBL873946 | 0.88 | DRD2 (0.45) | DRD2DRD3HTR1DSCN9ASCN5A | |
| SCHEMBL873945 | 0.88 | DRD2 (0.45) | DRD2DRD3HTR1DSCN9ASCN5A | |
| SCHEMBL8823791 | 0.84 | DRD2 (0.48) | DRD2DRD3HTR1DSCN9ASCN5A | |
| SCHEMBL4520723 | 0.84 | SCN9A (0.46) | DRD2SCN9ASCN5AKCNH2HTR2A | |
| SCHEMBL4750932 | 0.76 | SCN9A (0.50) | SCN9ASCN5AKCNH2 | |
| SCHEMBL4504199 | 0.75 | PGR (0.45) | DRD2DRD3SCN9ASCN5AKCNH2 | |
| SCHEMBL4519663 | 0.75 | TP53 (0.48) | DRD2DRD3SCN9ASCN5AKCNH2 | |
| SCHEMBL1285355 | 0.73 | DRD2 (0.46) | DRD2DRD3HTR1DDRD4HTR5A | |
| SCHEMBL21810914 | 0.73 | TP53 (0.53) | DRD2DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | HTR6, HTR1D, HTR1A | DRD2 56/4885DRD3 68/4885HTR1D 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.